---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-22-000064"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2022-11-17T23:59:59+00:00"
generated_at: "2026-06-21T16:43:35.891917+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech subsidiary Jeune reports up to 9-month durability for KB301 in PEARL-1 extension

## Summary
- Up to nine months durability of effect observed in patients aged 55-76 following high dose KB301.
- Mean Subject Satisfaction Score change from baseline ranged from 1.6 to 1.85 points at 7-9 months.
- Responder rate 62-70% based on Subject Satisfaction Score ≥1 point change; Investigator Assessments showed clinically meaningful difference in 70-76% of treated cheeks.
- Plan to initiate Phase 2 PEARL-2 study in 1H 2023 for fine lines and wrinkles.
- All adverse events were injection-site related, transitory, mild or moderate.

## SEC filing metadata
- accession: 0001711279-22-000064
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2022-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127922000064/0001711279-22-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127922000064/krys-20221117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-22-000064
- JSON: https://secwatch.observer/filing/0001711279-22-000064.json
- Plain text: https://secwatch.observer/filing/0001711279-22-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.